Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
Saved in:
| Title: | Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child. |
|---|---|
| Authors: | Keenan JC; Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA., Medford AJ; Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA., Dai CS; Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA., Wander SA; Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA., Spring LM; Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA., Bardia A; Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA. |
| Source: | Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2024 Jun; Vol. 24 (6), pp. 397-405. Date of Electronic Publication: 2024 Apr 26. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1744-8328 |
|---|---|
| DOI: | 10.1080/14737140.2024.2346188 |
